https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52387 Wed 28 Feb 2024 15:38:22 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53520 28.4 ng/mL) was independently associated with older age, use of beta-blockers, and number of MACE events within a 1 year period. In this patient cohort, elevated sST2 levels are associated with unplanned hospital admission due to MACE within 1 year, independent of the nature of the index cardiovascular admission.]]> Wed 28 Feb 2024 15:31:59 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45109 n = 230 patients (mean age 65, males n = 124 (53.9%)) were treated with bevacizumab during the study period. N = 28 patients were admitted to hospital for a major cardiovascular-related event. Higher total treatment dose (p < 0.05), concomitant hypertension (p = 0.005), diabetes (p = 0.04), atrial fibrillation (p = 0.03), and lack of use of statin therapy (p = 0.03) were key contributors to hospital admission. Conclusions: Results of our study highlight the fact that patients with concomitant baseline cardiovascular disease/risk factors are at an increased risk of cardiovascular hospitalization related to bevacizumab treatment. Careful baseline cardiovascular assessment may be an essential step to minimize cardiovascular complications.]]> Wed 26 Oct 2022 13:22:56 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28589 Wed 26 Aug 2020 11:11:04 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45703 Wed 24 Jan 2024 14:33:03 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51676 Wed 13 Sep 2023 15:22:04 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54400 Wed 13 Mar 2024 14:18:27 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:4497 Wed 11 Apr 2018 17:43:36 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26748 Wed 11 Apr 2018 16:04:18 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:4669 Wed 11 Apr 2018 11:26:34 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30832 Wed 11 Apr 2018 09:33:50 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45533 Wed 06 Mar 2024 15:04:41 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35805 Wed 04 Dec 2019 11:55:09 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44964 Tue 25 Oct 2022 13:31:32 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13823 Tue 24 Aug 2021 14:27:18 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44768 Tue 21 Mar 2023 16:48:12 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49887 Tue 13 Jun 2023 13:43:34 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50119 Tue 11 Jul 2023 15:40:02 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38188 Tue 10 Aug 2021 15:11:51 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54137 Tue 06 Feb 2024 11:49:57 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33721 Thu 28 Oct 2021 12:36:17 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:654 Thu 25 Jul 2013 09:10:27 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40221 n = 669), interviews (n = 92) and focus groups (n = 77). This research concentrated on participants' experiences in care, leaving care, life outcomes after care (education, employment, health, wellbeing and relationships), coping strategies and resilience, current service needs and usage and participation in organisations as well as the Royal Commission into Institutional Responses to Child Sexual Abuse. Most participants experienced extreme neglect and abuse while in care. Leaving care, often after years of institutionalisation, was generally a frightening and demoralising process. Despite these challenges, a number of participants demonstrated remarkable resilience. For many, however, these experiences had negative consequences in adulthood including serious physical and mental health problems. This often made adult learning, paid employment and positive relationships virtually impossible. Most survivors carry high levels of trauma and complex unmet needs. Implications for policy, practice and services are drawn from key findings.]]> Thu 14 Jul 2022 15:21:28 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48858 Thu 13 Apr 2023 13:29:31 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48868 Thu 13 Apr 2023 10:00:22 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41974 Thu 11 Apr 2024 14:52:18 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:1653 Thu 01 Aug 2019 17:18:16 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:1932 Sat 24 Mar 2018 08:33:19 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14395 Sat 24 Mar 2018 08:24:56 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13627 Sat 24 Mar 2018 08:15:19 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20812 Sat 24 Mar 2018 08:05:59 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:16903 Sat 24 Mar 2018 07:59:51 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19957 Sat 24 Mar 2018 07:58:32 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19558 Sat 24 Mar 2018 07:58:25 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20121 Sat 24 Mar 2018 07:51:45 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:5656 Sat 24 Mar 2018 07:44:03 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:370 Sat 24 Mar 2018 07:42:30 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:73 Sat 24 Mar 2018 07:42:08 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28637 Sat 24 Mar 2018 07:37:08 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32613 Mon 25 Jun 2018 14:21:11 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24011 Mon 23 Sep 2019 13:45:07 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32931 Enterobacter spp. possess chromosomal AmpC beta-lactamases that may be expressed at high levels. Previous studies have demonstrated a risk of relapsed bacteraemia following therapy with third generation cephalosporins (3GCs). What additional factors predict microbiological failure in Enterobacter bacteraemia is unclear. We aimed to determine factors associated with microbiological failure in Enterobacter bacteraemia. Methods: We retrospectively identified cases of bacteraemia caused by Enterobacter spp. occurring in four hospitals. Using a case-control design, we determined clinical risk factors for persistence or relapse defined as repeated positive blood cultures collected between 72 hours and up to 28 days post initial positive blood culture. Results: During the study period a total of 922 bacteraemia events caused by Enterobacter spp. in adults were identified. The overall risk of relapsed or persisting bacteraemia at 28 days was low (31 of 922, 3.4%), with only 2 patients experiencing emergent resistance to 3GCs. A total of 159 patients were included in the case-control study. Using multivariate logistic regression, independent predictors for relapse were a line-associated source of infection (OR 3.87; 95% CI 1.56-9.60, p = 0.004) and the presence of immunosuppression (OR 2.70; 95% CI 1.14-6.44, p = 0.02). On univariate analysis definitive therapy with a broad-spectrum beta-lactam-beta-lactamase inhibitor (BLBLI, e.g. piperacillin-tazobactam) was not associated with relapse (OR 1.83; 95% CI 0.64-5.21, p = 0.26) although the proportion of patients receiving a BLBLI as definitive therapy was relatively small (21/159, 13.2%). Conclusions: The risk of relapsed or persistent Enterobacter bacteraemia appears to be low in Australia. A line-associated source of infection and immunocompromise were significant independent predictors for relapse. Larger, preferably randomized, studies are needed to address whether BLBLIs represent an effective carbapenem-sparing option for Enterobacter bacteraemia.]]> Mon 23 Sep 2019 12:28:05 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49543 Mon 22 May 2023 08:45:40 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53277 Mon 20 Nov 2023 13:02:57 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51770 Mon 18 Sep 2023 14:30:25 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40779 Mon 18 Jul 2022 15:25:17 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41847 p = 0.010); but no differences in spontaneous abortions, term or preterm births. Conclusions: We report low pregnancy incidence rates, with increasing number of pregnancies conceived on DMT over the past 12-years. The median duration of DMT exposure in pregnancy was relatively short at one month.]]> Mon 15 Aug 2022 10:27:59 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52298 Mon 09 Oct 2023 10:11:19 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40197 Mon 08 Aug 2022 13:29:07 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39056 Cryptococcus neoformans and Cryptococcus gattii are yeasts responsible for invasive infection, primarily pulmonary and neurological. Their clinical epidemiology has been previously described in an Australian national study, but this included no data from the Hunter region, where we anecdotally noted a high incidence of infection. We aimed to describe the epidemiology, management and outcomes of cryptococcal disease in the Hunter region and to compare this with previous Australian data. Methods: We searched our laboratory database for positive cryptococcal antigen and culture results from January 2003-December 2016. We extracted demographic factors, risk factors, clinical presentation, treatment and outcomes from medical records. We used the 2010 census-derived estimated resident population to calculate population-based incidences. Results: Over a 13-year period, 107 patients had either a positive culture or a positive cryptococcal antigen with a compatible clinical syndrome. Of these, 46 (42.2%) were C. neoformans, 28 (25.7%) C. gattii, and 33 (30.3%) antigen only. The crude incidence (per million with 95% CI) for all disease was 9.5, and for culture proven disease was 2.5 for C. gattii and 4.1 for C. neoformans. Geospatial mapping by species revealed no evident cluster. Of the 63 patients where detailed information was available, around half were immunocompromised (3 [15%] for C. gattii and 25 [81%] for C. neoformans, p < 0.001). Complications were common, including visual loss (11 cases, 17.7%) and hearing loss (5 cases, 8%). Adverse outcomes at one year (death or neurological sequelae) occurred in 42%, and was significantly more likely (OR = 5.2, 95% CI 1.4-18.8) in those with raised intracranial pressure at baseline. Adverse outcomes were no more common in those treated with lower doses of liposomal amphotericin (≤150 mg/day, 5/10) than those treated with the recommended dose of 3-5 mg/kg (≥150 mg; 13/27). Conclusion: Although a rare disease, cryptococcosis is more common in the Hunter region than in other parts of Australia, and long-term sequelae are serious and common.]]> Mon 02 May 2022 15:13:36 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46553 Fri 25 Nov 2022 11:33:34 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:721 Fri 23 Mar 2018 15:43:41 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38179 Fri 03 Sep 2021 14:50:35 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47863 n = 45 hospitals) were analyzed. Differences in processes of care by the timing of discharge are described. Multilevel regression and survival analyses (up to 180 days postevent) were undertaken. Results: Among 30,649 registrants, 2621 (8.6%) were discharged on weekends (55% male; median age 74 years). Compared to those discharged on weekdays, patients discharged on weekends were more often patients with a transient ischemic attack (weekend 35% vs. 19%; p < 0.001) but were less often treated in a stroke unit (69% vs. 81%; p < 0.001), prescribed antihypertensive medication at discharge (65% vs. 71%; p < 0.001) or received a care plan if discharged to the community (47% vs. 53%; p < 0.001). After accounting for patient characteristics and clustering by hospital, patients discharged on weekends had a 1 day shorter length of stay (coefficient = -1.31, 95% confidence interval [CI] = -1.52, -1.10), were less often discharged to inpatient rehabilitation (aOR = 0.39, 95% CI = 0.34, 0.44) and had a greater hazard of death within 180 days (hazard ratio = 1.22, 95% CI = 1.04, 1.42) than those discharged on weekdays. Conclusions: Patients with stroke/transient ischemic attack discharged on weekends were more likely to receive suboptimal care and have higher long-term mortality. High quality of stroke care should be consistent irrespective of the timing of hospital discharge.]]> Fri 03 Feb 2023 14:00:52 AEDT ]]>